ICB therapy using a combination of PD-L1 and CTLA-4 blocking antibodies has been shown to reverse tumor-specific effector T cell exhaustion and increase the number of tumor-infiltrating lymphocytes (TILs) present, resulting in improved anti-tumor immune responses (68, 72, 74). This evidence concerns the gene CTLA4 and neoplasm.